Apollo Hospitals

The company successfully operationalized a 30-bed facility in Defence Colony, Delhi, which is part of the AHLL network expansion. (1 met across 1 tracked commitment)

The composite scheme involving the amalgamation of Keimed and the restructuring of the pharmacy business is underway to achieve the 100% ownership structure. (1 in progress across 1 tracked commitment)

Digital losses narrowed to INR 71 crore in Q2 FY26 from INR 101 crore in Q2 FY25, showing significant progress toward the breakeven target. (3 in progress across 3 tracked commitments)

The company expects EBITDA losses from the six new hospitals to be approximately INR 150 crore in the next fiscal year. — target: INR 150 crore (+1 more commitment)

Management plans to renovate several existing Apollo Spectra centers in the final quarter of the fiscal year.

Average Length of Stay (ALOS) dropped by 7% due to the adoption of new technologies like robotics and digital command centers, which improves bed turnover and efficiency. (1 expanding)

The core hospital business continues to expand through increased clinical intensity and pricing power, with revenue growing 14% and EBITDA margins improving from 24.1% to 24.8%. Growth was driven by an 11% increase in Average Revenue Per Inpatient (ARPP). (1 expanding)

Healthcare Services revenue grew 11% YoY, though slightly slower than the previous 14% growth rate. Occupancy dipped to 65% from 68% in the prior year, partly due to a 1.5% revenue impact from fewer patients from Bangladesh. (1 expanding)

Healthcare Services revenue grew 9% YoY in Q2 FY26, reaching ₹31,690 million. Growth was driven by a 2% increase in inpatient volumes and a 7% improvement in price/case mix. However, margins slightly contracted by 22 basis points due to a higher base of seasonal admissions in the previous year. (2 expanding across 1 engine)

Apollo is aggressively expanding its scale with a plan to add 4,300 capacity beds over the next 5 years, representing a ~38% increase from current census levels. (4 expanding)

Apollo has formalized a massive expansion plan to add 4,372 total beds (3,577 census beds) over the next 5 years, targeting a total capacity of ~13,000 census beds. This is a significant acceleration in planned capacity addition compared to previous maintenance cycles. (2 accelerating, 2 steady across 4 signals, 1 leading indicator)

Average Revenue per Inpatient (ARPP) grew by 9% YoY to ₹172,282, driven by an 8% improvement in price and case mix. This indicates a steady upward trajectory in clinical complexity and pricing power. (1 steady, 1 accelerating across 2 signals)

The company is deepening its insurance integration with 9 insurance provider tie-ups already established on the digital platform to improve revenue predictability. (1 new trend, 3 steady across 4 signals)

Apollo is investing in high-end medical technology, such as robotic surgery centers, to attract patients needing specialized care.

The Apollo 24|7 digital platform reached 41 million registered users, with Daily Active Users (DAU) growing 55% YoY to 7.9 Lakh. While the total user base is slightly lower than the 46Mn target mentioned in other periods, the engagement metrics (DAU) are accelerating sharply. (3 accelerating, 1 decelerating, 1 steady across 5 signals, 2 leading indicators)

The expansion risk remains high but stable as the company maintains its target to add ~3,577 census beds over the next 5 years with a total project cost of ~₹ 7,603 crs. The balance to be spent is ₹ 5,400 crs. (2 stable, 2 intensifying, 1 high-severity)

The risk is intensifying as the restructuring has entered a more complex phase with the approval of a 'Composite Scheme' involving the demerger of pharmacy distribution and amalgamation of Keimed. (5 intensifying)

The company's occupancy rates have slightly declined compared to the previous year, meaning expensive hospital beds are sitting empty more often, which hurts profit margins. [MARGIN_COST]

The risk is intensifying as occupancy rates fell further to 65% in Q1FY26 from 68% in Q1FY25. (3 intensifying, 1 stable)

The risk is easing as management reports that international patients from Bangladesh (a key driver for Northern/Metro hubs) began returning in October, and they are diversifying into new markets like Uzbekistan and Africa. (1 easing)